# Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)

> **NCT04979468** · PHASE3 · UNKNOWN · sponsor: **Societa' Italiana Di Malattie Infettive E Tropicali** · enrollment: 440 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** DOVATO

## Key facts

- **NCT ID:** NCT04979468
- **Lead sponsor:** Societa' Italiana Di Malattie Infettive E Tropicali
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-23
- **Primary completion:** 2023-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04979468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04979468, "Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04979468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*